Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SEC. 936 TWIN-PLANT PROJECTS HAVE CREATED NEARLY 5,500 JOBS

Executive Summary

SEC. 936 TWIN-PLANT PROJECTS HAVE CREATED NEARLY 5,500 JOBS: approximately 3,600 jobs in Caribbean Basin Initiative countries and 1,835 jobs in Puerto Rico, according to a recent report by Robert R. Nathan Associates. "Since January 1986, 27 twin-plant projects have been established, representing more than $29 mil. in investment," the report notes. Entitled "Section 936 and Economic Development in Puerto Rico," the report was sponsored by the Puerto Rico, U.S.A. Foundation. The idea of twin plants -- separate but integrated manufacturing facilities in Puerto Rico and another Caribbean island -- was first proposed by Puerto Rico Governor Hernandez Colon in 1985 to head off proposed changes to the possessions tax shelter. J&J, Schering-Plough and SmithKline were among the first Sec. 936 companies to support Governor Colon's "twin-plant" initiative by committing to open plants in Grenada in 1985. Of the 21 Sec. 936 companies to commit to twin plants in 1985, 16 were members of the Pharmaceutical Manufacturers Association. The report estimates that in 1984, Sec. 936 corporations announted for approximately 30% of all Puerto Rican jobs and 61% of all Puerto Rico manufacturing employment. According to the report, Sec. 936 companies directly employed 94,433 and were responsible for 268,703 jobs in 1984. Companies in the pharmaceutical and chemical industries were directly responsible for 13,169 jobs in 1984 -- or about 15% of total Sec. 936 employment -- but generated nearly 62,000 jobs -- or nearly one-quarter of all Sec. 936 employment. Employment in Sec. 936 corporations in the chemical and allied products industries, which includes pharmaceuticals, rose 4.1% annually in the 10-year period from 1975 to 1985, the Nathan report says. As of 1984, Sec. 936 corporations accounted for 82% of all employment in the relatively high-paying chemical and allied products industries. The report underscores the negative impact that uncertainties over changes in the tax law have had on Puerto Rico's economy during the 1980s. It estimates that 11,600 jobs were delayed as a short term response to TEFRA in 1982 and the Tax Reform Act in 1986. Based on a recent survey of 41 Sec. 936 corporations with 62 plants in Puerto Rico, the consulting firm found that "at least $60 mil. of investment and 1,000 direct manufacturing jobs were permanently lost due to a perception by businesses of long-term instability in Sec. 936." In addition, the report estimates that 1,900 indirect jobs were permanently lost.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel